Apremilast - Generic Drug Details

What are the generic sources for apremilast and what is the scope of patent protection?

Apremilast is the generic ingredient in three branded drugs marketed by Amgen Inc, Alkem Labs Ltd, Amneal, Annora, Aurobindo Pharma Ltd, Dr Reddys, Glenmark Pharms Ltd, Macleods Pharms Ltd, Mankind Pharma, MSN, Shilpa, Teva Pharms Usa Inc, Torrent, and Unichem, and is included in fifteen NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Apremilast has one hundred and three patent family members in twenty-seven countries.

There are twenty-eight drug master file entries for apremilast. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for apremilast

International Patents:	103
US Patents:	8
Tradenames:	3
Applicants:	14
NDAs:	15
Drug Master File Entries:	28
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	128
Patent Applications:	4,500
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for apremilast
What excipients (inactive ingredients) are in apremilast?	apremilast excipients list
DailyMed Link:	apremilast at DailyMed

Recent Clinical Trials for apremilast

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	NA
University of California, San Francisco	PHASE4
Syeda Sana Zaman	EARLY_PHASE1

See all apremilast clinical trials

Generic filers with tentative approvals for APREMILAST

Applicant	Application No.	Strength	Dosage Form
		30MG	TABLET;ORAL
		20MG	TABLET;ORAL
		10MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for apremilast

Drug Class	Phosphodiesterase 4 Inhibitor
Mechanism of Action	Phosphodiesterase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for apremilast

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for APREMILAST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OTEZLA	Tablets	apremilast	10 mg, 20 mg and 30 mg	205437	11	2018-03-22

US Patents and Regulatory Information for apremilast

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa Inc	APREMILAST	apremilast	TABLET;ORAL	211897-002	Aug 18, 2022		DISCN	No	No
Annora	APREMILAST	apremilast	TABLET;ORAL	211878-002	Jul 26, 2023	AB	RX	No	No
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	AB	RX	Yes	No
Torrent	APREMILAST	apremilast	TABLET;ORAL	211834-002	Jun 20, 2025		DISCN	No	No

Expired US Patents for apremilast

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014
Amgen Inc	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014

EU/EMA Drug Approvals for apremilast

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amgen Europe BV	Otezla	apremilast	EMEA/H/C/003746Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).	Authorised	no	no	no	2015-01-15

International Patents for apremilast

Country	Patent Number	Title	Estimated Expiration
Canada	2479666	(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: LEURS PROCEDES D'UTILISATION ET LEURS COMPOSITIONS ((+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF)
European Patent Office	4346762
Japan	2005525386
Denmark	1485087

Supplementary Protection Certificates for apremilast

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	1990037-2	Sweden		PRODUCT NAME: APREMILAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/981 20150116
2962690	300994	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
2962690	365 14-2019	Slovakia		PRODUCT NAME: APREMILAST VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/981 20150116
2962690	C201930044	Spain		PRODUCT NAME: APREMILAST O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/14/981; DATE OF AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/981; DATE OF FIRST AUTHORISATION IN EEA: 20150115

Apremilast Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Key Market Dynamics for Apremilast?

Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis and psoriatic arthritis. Its market is shaped by several factors:

• Competitive Landscape: Dominated by biologics such as adalimumab, etanercept, and ustekinumab. Apremilast competes on oral administration, which appeals to patients preferring non-injectable options.

• Market Penetration and Prescribing Trends: Since its FDA approval in 2014, apremilast has gained a moderate share within psoriasis and psoriatic arthritis markets. Its uptake faces challenges from newer biologics with higher efficacy profiles.

• Regulatory Approvals and Indications: Expanded indications, including active psoriatic arthritis without prior biologic use, bolster its market position. Continued trials aim to address additional conditions such as Behçet's disease and ulcerative colitis.

• Pricing and Reimbursement: Priced higher than traditional systemic therapies; reimbursement policies influence accessibility. As a branded drug, patent protection restricts generic competition until expiration.

• Manufacturing and Supply Chain: Market stability benefits from Novartis’ global manufacturing network, ensuring supply continuity.

What Is the Current and Projected Financial Performance of Apremilast?

Financial data relies heavily on Novartis' disclosures and market analyses:

• Sales Revenue (2022): Approximately USD 920 million globally, representing a decline from peak sales of USD 1.2 billion in 2019. The decline correlates with increased competition and market saturation.

• Market Share: Estimated at around 8% in the psoriasis market and similar in psoriatic arthritis, trailing biologics which hold over 50% combined.

• Revenue Breakdown: North America accounts for roughly 60% of sales; Europe contributes 25%, with remaining revenue from Asia-Pacific and other regions.

• Profitability: Gross margins reported at approximately 85%. Net profit margins for apremilast as part of Novartis' immunology portfolio are approximately 30%, though specific margins are consolidated.

• Forecast for 2023-2027:

  • CAGR (Compound Annual Growth Rate): Projected at 2-3%, reflecting slow market growth and competition.

  • Growth Drivers: Expansion into new indications, such as Behçet’s disease, and increased use in off-label areas.

  • Challenges: Competition from newer oral agents, biosimilars once patent expires, and market saturation.

• Patent and Regulatory Landscape: Patent expiration primarily forecasted around 2024-2026, opening potential for biosimilar entry which could significantly impact revenues.

What Are Future Risks and Opportunities?

• Risks:

  • Patent expiry risks leading to biosimilar competition, potentially eroding sales by 50% within three years post-generic entry.

  • Market shift toward biologics and biosimilars, which may provide higher efficacy but reduce apremilast’s market share.

  • Regulatory delays in new indications or formulations could limit growth.

• Opportunities:

  • Expansion into underserved markets, especially in Asia-Pacific regions where psoriasis and psoriatic arthritis are increasing.

  • Development of fixed-dose combinations, improving patient adherence.

  • Data from ongoing trials could support label expansion, extending product lifecycle.

How Do Market and Financial Metrics Compare to Competitors?

Drug	Indication	Sales (2022)	Market Share	Approval Year	Patents Expiry	Delivery Mode
Apremilast	Psoriasis, Psoriatic Arthritis	USD 920M	8%	2014	2024-2026	Oral
Adalimumab	Psoriasis, Rheumatoid Arthritis	USD 21.8B (2022)	50%+	2002	2034+	Injectable
Secukinumab	Psoriasis	USD 4.4B (2022)	20%	2015	2030	Injectable

How Will Market Dynamics Shape Financial Outcomes?

The expected decline in apremilast revenues aligns with the lifecycle pattern of many branded small-molecule drugs approaching patent expiration. It faces pressure from biosimilar biologics offering similar efficacy at lower prices post-patent expiry.

Investments in new indications and formulations aim to extend its revenue-generating period. Nonetheless, the ultimate decline depends heavily on biosimilar market entries and acceptance of alternative therapies.

Key Takeaways

• Apremilast's revenue peaked around 2019 and has seen a gradual decline due to competition and patent expiries.
• The drug occupies a niche for oral therapies but struggles against biologics' higher efficacy.
• Future growth hinges on regulatory approvals for new indications and geographic expansion, especially in Asia-Pacific.
• Patent expiry between 2024 and 2026 threatens significant revenue erosion unless mitigated by new markets or indications.
• Overall, apremilast remains a moderately significant product within Novartis’ immunology portfolio; its trajectory reflects broader industry trends toward biologics and biosimilars.

FAQs

1. What is the primary driver of apremilast’s revenue decline? Patent expiration and rising biosimilar competition from biologic therapies.

2. When will generic versions of apremilast likely enter the market? Patents are expected to expire around 2024 to 2026, depending on jurisdictions.

3. Are there efforts to expand apremilast’s approved uses? Yes, clinical trials explore indications such as Behçet’s disease and ulcerative colitis, potentially extending market life.

4. How does apremilast’s efficacy compare to biologics? Biologics generally show higher efficacy but are injectable; apremilast offers a convenient oral route with moderate efficacy.

5. What strategic moves could sustain apremilast’s market position? Entering emerging markets, developing combination therapies, and securing new indications are key.

---

Sources:

1. Novartis Annual Reports and Financial Statements (2022).
2. IQVIA Market Data, 2022.
3. FDA and EMA approval documents.
4. EvaluatePharma, 2022.
5. Industry analyst reports on biosimilars and biologics market trends.